San Francisco is no stranger to eliciting change and innovation.
Home to a long list of tech powerhouses, pharmaceutical companies and startups that will soon be household names, it is a city that isn’t afraid to turn ideas into reality. This is exactly why we’re here, in The City by the Bay, to better serve our rapidly growing client base with a local team that understands just how quickly innovation can happen, and stands ready to navigate any landscape to forge the next big thing.
With a new therapeutic option for those suffering from epileptic seizures that had high future potential with current, anticipated and potential indications, a name needed to be created that would find itself appropriate for all stages of the product lifecycle. This is where our ability to tap into the extensive experience and ability of our market research team came into play.
Abbott Cardiovascular, with growing equity in its XIENCE brand of drug eluting stent products, looked to leverage this equity to expand the portfolio for its next generation of products. Since we’d already engaged with Abbott on previous XIENCE work, we were well-equipped to develop these new brand names.